Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies

• Chris Wynne,
• Abundio Balgos,
• Jingxin Li,
• Paul Hamilton,
• Louie Tirador,
• Anjuli May Jaen,
• Chen Mo,
• Zijing Yue,
• Ying Ma,
• Qingshuang Wang,
• Rendu Wen,
• Zheng Yao,
• Jiaping Yu,
• Wenrong Yao,
• Jianhui Zhang,
• Hui Zheng,
• Kunxue Hong,
• Fengcai Zhu,
• Yong Liu

Affiliations

Chris Wynne

New Zealand Clinical Research

Abundio Balgos

Philippines Clinical Research, The Health Centrum

Jingxin Li

NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention)

Paul Hamilton

New Zealand Clinical Research

Louie Tirador

Philippines Clinical Research, St. Paul’s Hospital

Anjuli May Jaen

Philippines Clinical Research, The Medical City Iloilo

Chen Mo

Jiangsu Recbio Technology Co., Ltd.

Zijing Yue

Jiangsu Recbio Technology Co., Ltd.

Ying Ma

Jiangsu Recbio Technology Co., Ltd.

Qingshuang Wang

Jiangsu Recbio Technology Co., Ltd.

Rendu Wen

Jiangsu Recbio Technology Co., Ltd.

Zheng Yao

Jiangsu Recbio Technology Co., Ltd.

Jiaping Yu

Jiangsu Recbio Technology Co., Ltd.

Wenrong Yao

Jiangsu Recbio Technology Co., Ltd.

Jianhui Zhang

Jiangsu Recbio Technology Co., Ltd.

Hui Zheng

School of Public Health, Southeast University

Kunxue Hong

Jiangsu Recbio Technology Co., Ltd.

Fengcai Zhu

NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention)

Yong Liu

Jiangsu Recbio Technology Co., Ltd.